French defence company Exosens said on Tuesday it would triple thermal-camera production ‌capacity in 2026 to meet growing demand from ‌drone and counter-drone applications, as it reported a 15.3% rise ​in first-half revenue and raised its full-year outlook. The night-vision gear maker said it now expected full-year revenue and adjusted EBITDA to come in toward the upper end ‌of its respective ⁠guidance ranges of 520 million to 540 million euros and 168 million to ⁠178 million euros. It also expects capital expenditure of around 9% of 2026 revenue, driven by production-capacity expansion ​in Europe ​and the United States.

As the European markets navigate a landscape of stalled geopolitical negotiations and fluctuating oil prices, the pan-European STOXX Europe 600 Index has remained relatively stable, with corporate earnings showing signs of positive momentum. In this environment, identifying stocks that might be trading below their fair value can be particularly appealing to investors seeking opportunities amidst broader economic uncertainties.

Exosens' sales jumped 19.7% in the first quarter, driven by booming demand for drones and anti-drone ‌systems, a trend the French defence technology group is betting on to ‌carry future growth. Exosens' products are in high demand as they can be deployed rapidly unlike large, capital-intensive systems, ​and the company has a strong offering and growing momentum in its tactical drones and drone-detection technologies, Bernstein analyst Aleksander Peterc said.

Exosens secured record orders for its advanced imaging solutions in unmanned defense platforms. The company signed a major deal with a European autonomous air defense developer for ultra compact thermal camera cores used in next generation interceptor drones. These contract wins highlight Exosens’ role as a digital imaging partner for defense customers across Europe, the U.S., and Asia. For investors tracking ENXTPA:EXENS, this order momentum comes as the share price stands at €63.65 and...

With no single headline event driving attention, Exosens (ENXTPA:EXENS) is drawing interest after a year of strong share price and earnings growth. This is raising questions about how its current valuation aligns with recent performance. See our latest analysis for Exosens. Recent trading reflects a cooling phase after a strong run, with the latest share price at €63.65, a 90 day share price return of 10.7% and a 1 year total shareholder return of 90.16%. This suggests momentum has been...

This article is designed to help you think clearly about whether Exosens is attractively priced after its strong run, or whether much of the value case may already be reflected in the current valuation. The share price is €56.10, with returns of 6.0% over 7 days, 19.4% over 30 days, 12.2% year to date, and 178.0% over 1 year. That naturally raises questions about how much is already baked into the price. Recent coverage of Exosens has focused on its position in the capital goods space and on...

Recent performance puts Exosens in focus Exosens (ENXTPA:EXENS) has quietly turned into a strong performer, with the stock up around 168% over the past year and 7% in the past 3 months, drawing fresh attention from investors. See our latest analysis for Exosens. That surge is not just a one off move. A strong year to date share price return alongside a robust 1 year total shareholder return suggests momentum is still building as the market reassesses Exosens growth profile and risk. If...

As the European market navigates a mixed landscape, with the STOXX Europe 600 Index recently pulling back after reaching new highs and interest rate expectations from the ECB remaining steady, investors are increasingly focused on identifying opportunities among undervalued stocks. In such an environment, a good stock is often characterized by its potential to trade below its estimated intrinsic value, offering room for appreciation as market conditions evolve.

Theon International Plc recently announced the acquisition of a 9.8% stake in Exosens for €54 per share, funded through a new €300 million revolving credit facility from a consortium of international and Greek banks; the company also entered into a $15 million strategic investment agreement with Kopin Corporation to collaborate on military-grade display technology. This combination of a significant debt-financed acquisition and expanded technology partnerships highlights Theon's ambitions to...

On September 29, 2025, the Spanish Ministry of Defense announced it had signed a major supply contract with Exosens' subsidiary NVLS to provide 17,000 night vision monoculars, equipped with 16 mm 4G intensifier tubes, for delivery from 2025 to 2028. This procurement marks Spain as the first country worldwide to deploy such advanced wide field-of-view night vision technology across its armed forces, supporting both military modernization and European industrial sovereignty. We will explore...